Retinoblastoma

Pediatric Clinics of North America

Volumn 62, Issue 1, 2015, Pages 201-223

  Rodriguez Galindo, Carlos ^a   Orbach, Darren B ^a   VanderVeen, Deborah ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Germline mutation; Retinoblastoma; Second malignant neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; RETINOBLASTOMA BINDING PROTEIN 1; TOPOTECAN; VINCRISTINE;

BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CRYOTHERAPY; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; GENETIC COUNSELING; GERM LINE; HIGH RISK PATIENT; HUMAN; HYPERTHERMIC THERAPY; LASER COAGULATION; METASTASIS; RB1 GENE; RETINOBLASTOMA; REVIEW; SALVAGE THERAPY; SIGNAL TRANSDUCTION; TUMOR GENE; GENETICS; MUTATION; PATHOLOGY; RETINAL NEOPLASMS; TUMOR SUPPRESSOR GENE;

GENES, RETINOBLASTOMA; HUMANS; MUTATION; NEOPLASM STAGING; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 84915748733     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2014.09.014     Document Type: Review

References (134)

1. Young JL, Smith MA, Roffers SD, etal. Retinoblastoma. SEER Monograph. 1999: 73-78.
2. Parkin D.M., Stiller C.A., Draper G.J., et al. The international incidence of childhood cancer. Int J Cancer 1988, 42:511-520.
3. Stiller C., Parkin D. Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull 1996, 52:682-703.
4. de Camargo B., de Oliveira Santos M., Rebelo M., et al. Cancer incidence among children and adolescents in Brazil: first report of 14 population-based cancer registries. Int J Cancer 2010, 126:715-720.
5. Fajardo-Gutierrez A., Juarez-Ocana S., Gonzalez-Miranda G., et al. Incidence of cancer in children residing in ten jurisdictions of the Mexican Republic: importance of the cancer registry (a population-based study). BMC Cancer 2007, 7:68.
6. Juarez-Ocana S., Palma-Padilla V., Gonzalez-Miranda G., et al. Epidemiological and some clinical characteristics of neuroblastoma in Mexican children (1996-2005). BMC Cancer 2009, 9:266.
7. Bunin G.R., Meadows A.T., Emanuel B.S., et al. Pre- and postconception factors associated with sporadic heritable and nonheritable retinoblastoma. Cancer Res 1989, 49:5730-5735.
8. Orjuela M., Titievsky L., Liu X., et al. Fruit and vegetable intake during pregnancy and risk for development of sporadic retinoblastoma. Cancer Epidemiol Biomarkers Prev 2005, 14:1433-1440.
9. Orjuela M.A., Cabrera-Muñoz L., Paul L., et al. Risk of retinoblastoma is associated with a maternal polymorphism in dihydrofolatereductase (DHFR) and prenatal folic acid intake. Cancer 2012, 118:5912-5919.
10. Dryja T.P., Mukai S., Petersen R., et al. Parental origin of mutations of the retinoblastoma gene. Nature 1989, 339:556-558.
11. Moll A.C., Imhof S.M., Kuik J., et al. High parental age is associated with sporadic hereditary retinoblastoma: The Dutch Retinoblastoma Register 1862-1994. Hum Genet 1996, 98:109-112.
12. Heck J., Lombardi C., Meyers T., et al. Perinatal characteristics and retinoblastoma. Cancer Causes Control 2012, 23:1567-1575.
13. Bunin G.R., Petrakova A., Meadows A.T., et al. Occupations of parents of children with retinoblastoma: a report from the Children's Cancer Study Group. Cancer Res 1990, 50:7129-7133.
14. Jemal A., Devesa S.S., Fears T.R., et al. Retinoblastoma incidence and sunlight exposure. Br J Cancer 2000, 82:1875-1878.
15. Hooper M.L. Is sunlight an aetiological agent in the genesis of retinoblastoma?. Br J Cancer 1999, 79:1273-1276.
16. Heck J.E., Park A.S., Qiu J., et al. Retinoblastoma and ambient exposure to air toxics in the perinatal period. JExpo Sci Environ Epidemiol 2013, [Epub ahead of print].
17. Niemitz E.L., Feinberg A.P. Epigenetics and assisted reproductive technology: a call for investigation. Am J Hum Genet 2004, 74:599-609.
18. Moll A., Imhof S., Cruysberg J.R., et al. Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet 2003, 361:309-310.
19. Marees T., Dommering C.J., Imhof S.M., et al. Incidence of retinoblastoma in Dutch children conceived by IVF: an expanded study. Hum Reprod 2009, 24:3220-3224.
20. Bunin G.R., Felice M.A., Davidson W., et al. Medical radiation exposure and risk of retinoblastoma resulting from new germline RB1 mutation. Int J Cancer 2011, 128:2393-2404.
21. Knudson A.G. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci USA 1971, 72:820-823.
22. Lee W.H., Bookstein R., Hong F., et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987, 235:1394-1399.
23. Friend S.H., Bernards R., Rogelj S., et al. Ahuman DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986, 323:643-646.
24. Laurie N.A., Donovan S.L., Shih C.S., et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006, 444:61-66.
25. Dimaras H., Khetan V., Halliday W., et al. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 2008, 17:1363-1372.
26. Hernando E., Nahle Z., Juan G., et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004, 430:797-802.
27. Manning A.L., Longworth M.S., Dyson N.J. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev 2010, 24:1364-1376.
28. Zhang J., Benavente C.A., McEvoy J., et al. Anovel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012, 481:329-334.
29. Rushlow D.E., Mol B.M., Kennett J.Y., et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol 2013, 14:327-334.
30. McEvoy J., Nagahawatte P., Finkelstein D., et al. RB1 inactivation by chromothripsis in human retinoblastoma. Oncotarget 2014, 5(2):438-450.
31. Goddard A.G., Kingston J.E., Hungerford J.L. Delay in diagnosis of retinoblastoma: risk factors and treatment outcome. Br J Ophthalmol 1999, 83:1320-1323.
32. Chantada G.L., Qaddoumi I., Canturk S., et al. Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer 2011, 56:341-348.
33. Committee on Practice and Ambulatory Medicine, Section on Ophthalmology, American Association of Certified Orthoptists, American Association for Pediatric Ophthalmology and Strabismus, American Academy of Ophthalmology Eye examination in infants, children, and young adults by pediatricians. Pediatrics 2003, 111:902-907.
34. Draper G.J., Sanders B.M., Brownhill P.A., et al. Patterns of risk of hereditary retinoblastoma and applications to genetic counselling. Br J Cancer 1992, 66:211-219.
35. Richter S., Vandezande K., Chen N., et al. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 2003, 72:253-269.
36. Houdayer C., Gauthier-Villars M., Laug A., et al. Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat 2004, 23:193-202.
37. Abramson D.H., Frank C.M., Susman M., et al. Presenting signs of retinoblastoma. JPediatr 1998, 132:505-508.
38. Baud O., Cormier-Daire V., Lyonnet S., et al. Dysmorphic phenotype and neurological impairment in 22 retinoblastoma patients with constitutional cytogenetic 13q deletion. Clin Genet 1999, 55:478-482.
39. Holladay D.A., Holladay A., Montebello J.F., et al. Clinical presentation, treatment, and outcome of trilateral retinoblastoma. Cancer 1991, 67:710-715.
40. Wright K.D., Qaddoumi I., Patay Z., et al. Successful treatment of early detected trilateral retinoblastoma using standard infant brain tumor therapy. Pediatr Blood Cancer 2010, 55:570-572.
41. Kivel T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. JClin Oncol 1999, 17:1829-1837.
42. Beck-Popovic M., Balmer A., Maeder P., et al. Benign pineal cysts in children with bilateral retinoblastoma: a new variant of trilateral retinoblastoma?. Pediatr Blood Cancer 2006, 46:755-761.
43. Ramasubramanian A., Kytasty C., Meadows A.T., et al. Incidence of pineal gland cyst and pineoblastoma in children with retinoblastoma during the chemoreduction era. Am J Ophthalmol 2013, 156:825-829.
44. Beets-Tan R.G., Hendriks M.J., Ramos L.M., et al. Retinoblastoma: CT and MRI. Neuroradiology 1994, 36:59-62.
45. Wilson M.W., Rodriguez-Galindo C., Billups C., et al. Lack of correlation between the histologic and magnetic resonance imaging results of optic nerve involvement in eyes primarily enucleated for retinoblastoma. Ophthalmology 2009, 116:1558-1563.
46. Khurana A., Eisenhut C., Wan W., et al. Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma. Eur Radiol 2013, 23:1271-1280.
47. Song K.D., Eo H., Kim J.H., et al. Can preoperative MR imaging predict optic nerve invasion of retinoblastoma?. Eur J Radiol 2012, 81:4041-4045.
48. Laurent V.E., Sampor C., Solernou V., et al. Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. Eur J Cancer 2013, 49:2892-2899.
49. Chantada G.L., Rossi J., Casco F., et al. An aggressive bone marrow evaluation including immunocytology with GD2 for advanced retinoblastoma. JPediatr Hematol Oncol 2006, 28:369-373.
50. Terry J., Calicchio M.L., Rodriguez-Galindo C., et al. Immunohistochemical expression of CRX in extracranial malignant small round cell tumors. Am J Surg Pathol 2012, 36:1165-1169. 10.097/PAS.0b013e3182601d84.
51. Reese A.B., Ellsworth R.M. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol 1963, 67:164-172.
52. Shields C.L., Mashayekhi A., Au A.K., et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006, 113:2276-2280.
53. Murphree A.L. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005, 18:41-53.
54. Grabowski E.F., Abramson D.H. Intraocular and extraocular retinoblastoma. Hematol Oncol Clin North Am 1987, 1:721-735.
55. Pratt C.B., Fontanesi J., Lu X., et al. Proposal for a new staging scheme for intraocular and extraocular retinoblastoma based on an analysis of 103 globes. Oncologist 1997, 2:1-5.
56. AJCC Retinoblastoma. AJCC cancer staging manual 2010, 562-563. Springer, New York. 7th edition. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
57. Chantada G., Doz F., Antonelli C.B.G., et al. Aproposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006, 47:801-805.
58. Chantada G.L., Sampor C., Bosaleh A., et al. Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients. JAMA Ophthalmol 2013, 131:1127-1134.
59. Rodriguez-Galindo C., Chantada G.L., Haik B., et al. Retinoblastoma: current treatment and future perspectives. Curr Treat Options Neurol 2007, 9:294-307.
60. Shields C.L., Shields J.A. Recent developments in the management of retinoblastoma. JPediatr Ophthalmol Strabismus 1999, 36:8-18.
61. Wilson M. Treatment of intraocular retinoblastoma. Retinoblastoma 2010, 91-99. Springer, New York (NY). C. Rodriguez-Galindo, M.W. Wilson (Eds.).
62. Shields J.A., Shields C.L., DePotter P. Photocoagulation of retinoblastoma. Int Ophthalmol Clin 1993, 33:95-99.
63. Shields J.A., Parsons H., Shields C.L., et al. The role of cryotherapy in the management of retinoblastoma. Am J Ophthalmol 1989, 108:260-264.
64. Shields C.L., Santos M.C., Diniz W., et al. Thermotherapy for retinoblastoma. Arch Ophthalmol 1999, 117:885-893.
65. Scott I.U., Murray T.G., Feuer W.J., et al. External beam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. Arch Ophthalmol 1999, 117:766-770.
66. Hungerford J.L., Toma N.M., Plowman P.N., et al. External beam radiotherapy for retinoblastoma: I. Whole eye technique. Br J Ophthalmol 1995, 79:109-111.
67. Toma N.M., Hungerford J.L., Plowman P.N., et al. External beam radiotherapy for retinoblastoma: II. Lens sparing technique. Br J Ophthalmol 1995, 79:112-117.
68. Merchant T.E. Radiation therapy in the management of retinoblastoma retinoblastoma 2010, 55-64. Springer, Retinoblastoma. New York (NY). Rodriguez-Galindo, M.W. Wilson (Eds.).
69. Fass D., McCormick B., Abramson D., et al. Cobalt60 plaques in recurrent retinoblastoma. Int J Radiat Oncol Biol Phys 1991, 21:625-627.
70. Freire J.E., De Potter P., Brady L.W., et al. Brachytherapy in primary ocular tumors. Semin Surg Oncol 1997, 13:167-176.
71. Al-Haj A.N., Lobriguito A.M., Lagarde C.S. Radiation dose profile in 125I brachytherapy: an 8-year review. Radiat Prot Dosimetry 2004, 111:115-119.
72. Abouzeid H., Moeckli R., Gaillard M.C., et al. (106)Ruthenium brachytherapy for retinoblastoma. Int J Radiat Oncol Biol Phys 2008, 71:821-828.
73. Chantada G.L., Davila M.T., Fandiño A., et al. Retinoblastoma with low risk for extraocular relapse. Ophthalmic Genet 1999, 20:133-140.
74. Merchant T.E., Gould C.J., Hilton N.E., et al. Ocular preservation after 36 Gy external beam radiation therapy for retinoblastoma. JPediatr Hematol Oncol 2002, 24:246-249.
75. Berry J.L., Jubran R., Kim J.W., et al. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer 2013, 60:688-693.
76. Shields C.L., Ramasubramanian A., Thangappan A., et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology 2009, 116:544-551.e1.
77. Sethi R.V., Shih H.A., Yeap B.Y., et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 2014, 120:126-133.
78. Ross G., Lipper E.G., Abramson D., et al. The development of young children with retinoblastoma. Arch Pediatr Adolesc Med 2001, 155:80-83.
79. Gobin Y., Dunkel I.J., Marr B.P., et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 2011, 129:732-737.
80. Honavar S.G., Singh A.D., Shields C.L., et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002, 120:923-931.
81. Uusitalo M.S., Van Quill K.R., Scott I.U., et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001, 119:41-48.
82. Khelfaoui F., Validire P., Auperin A., et al. Histopathologic risk factors in retinoblastoma. A retrospective study of 172 patients treated in a single institution. Cancer 1996, 77:1206-1213.
83. Chantada G., Fandiño A., Davila M.T., et al. Results of a prospective study for the treatment of retinoblastoma. Cancer 2004, 100:834-842.
84. Chantada G.L., Casco F., Fandiño A.C., et al. Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology 2007, 114:2083-2089.
85. Cuenca A., Giron F., Castro D., et al. Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol 2009, 127:1006-1010.
86. Bosaleh A., Sampor C., Solernou V., et al. Outcome of children with retinoblastoma and isolated choroidal invasion. Arch Ophthalmol 2012, 130:724-729.
87. Kaliki S., Shields C.L., Shah S.U., et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol 2011, 129:1422-1427.
88. Kaliki S., Shields C.L., Rojanaporn D., et al. High-risk retinoblastoma based on International Classification of Retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 2013, 120:997-1003.
89. Schvartzman E., Chantada G., Fandiño A., et al. Results of a stage-based protocol for the treatment of retinoblastoma. JClin Oncol 1996, 14:1532-1536.
90. Abramson D.H., Frank C.M. Second nonocular tumors in survivors of bilateral retinoblastoma. A possible age effect on radiation-related risk. Ophthalmology 1998, 105:573-580.
91. Shields C.L., Honavar S.G., Meadows A.T., et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002, 133:657-664.
92. Gündüz K., Shields C.L., Shields J.A., et al. The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma. Arch Ophthalmol 1998, 116:1613-1617.
93. Shields C.L., Shields J.A., Needle M., et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997, 104:2101-2111.
94. Gombos D.S., Kelly A., Coen P.G., et al. Retinoblastoma treated with primary chemotherapy alone: the significance of tumor size, location, and age. Br J Ophthalmol 2002, 86:80-83.
95. Shields C.L., Honavar S.G., Shields J.A., et al. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002, 120:460-464.
96. Laurie N.A., Gray J.K., Zhang J., et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 2005, 11:7569-7578.
97. Qaddoumi I., Billups C.A., Tagen M., et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer 2012, 118:5663-5670.
98. Kaneko A., Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol 2003, 33:601-607.
99. Suzuki S., Yamane T., Mohri M., et al. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 2011, 118:2081-2087.
100. Inomata M., Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res 1987, 78:858-868.
101. Schaiquevich P., Buitrago E., Taich P., et al. Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci 2012, 53:4205-4212.
102. Mohri M. The technique of selective ophthalmic arterial infusion for conservative treatment of recurrent intraocular retinoblastoma (in Japanese). Keio Igaku 1993, 70:679-687.
103. Abramson D.H., Dunkel I.J., Brodie S.E., et al. Aphase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma: initial results. Ophthalmology 2008, 115:1398-1404.
104. Shields C.L., Bianciotto C.G., Jabbour P., et al. Intra-arterial chemotherapy for retinoblastoma: Report no. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 2011, 129:1399-1406.
105. Klufas M.A., Gobin Y.P., Marr B., et al. Intra-arterial chemotherapy as a treatment for intraocular retinoblastoma: alternatives to direct ophthalmic artery catheterization. AJNR Am J Neuroradiol 2012, 33:1608-1614.
106. Abramson D.D., Dunkel I.J., Brodie S.E., et al. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol 2010, 128:370-372.
107. Abramson D.H., Dunkel I.J., Brodie S.E., et al. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 2010, 117:1623-1629.
108. Francis J., Gobin Y., Dunkel I., et al. Carboplatin+/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. PLoS One 2013, 8:e72441.
109. Abramson D.H., Marr B.P., Brodie S.E., et al. Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS One 2012, 7:e34120.
110. Schaiquevich P., Ceciliano A., Millan N., et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer 2013, 60:766-770.
111. Marr B.P., Brodie S.E., Dunkel I.J., et al. Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol 2012, 96:1300-1303.
112. Abramson D.H., Marr B.P., Dunkel I.J., et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 2012, 96:499-502.
113. Gobin Y., Dunkel I., Marr B.P., et al. Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One 2012, 7:e44322.
114. Tse B.C., Steinle J.J., Johnson D., et al. Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: Histopathologic findings. JAMA Ophthalmol 2013, 131:903-911.
115. Eagle R.C., Shields C.L., Bianciotto C., et al. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol 2011, 129:1416-1421.
116. Abramson D.H. Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol 2011, 129:1492-1494.
117. Brodie S., Munier F., Francis J., et al. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Doc Ophthalmol 2013, 126:79-84.
118. Gobin Y., Rosenstein L.M., Marr B.P., et al. Radiation exposure during intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol 2012, 130:403-405.
119. Vijayakrishnan R., Shields C.L., Ramasubramanian A., et al. Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned?. Arch Ophthalmol 2010, 128:1427-1431.
120. Munier F.L., Gaillard M.C., Balmer A., et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 2012, 96:1078-1083.
121. Shields C.L., Manjandavida F.P., Arepalli S., et al. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol 2014, 132:319-325.
122. Antonelli C.B., Steinhorst F., Ribeiro K.C., et al. Extraocular retinoblastoma: a 13-year experience. Cancer 2003, 98:1292-1298.
123. Menon B.S., Reddy S.C., Maziah W., et al. Extraocular retinoblastoma. Med Pediatr Oncol 2000, 35:75-76.
124. Doz F., Khelfaoui F., Mosseri V., et al. The role of chemotherapy in orbital involvement of retinoblastoma. Cancer 1994, 74:722-732.
125. Chantada G., Fandiño A., Casak S., et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol 2003, 40:158-161.
126. Namouni F., Doz F., Tanguy M.L., et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 1997, 33:2368-2375.
127. Dunkel I.J., Khakoo Y., Kernan N.A., et al. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer 2010, 55:55-59.
128. Kleinerman R.A., Tucker M.A., Tarone R.E., et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. JClin Oncol 2005, 23:2272-2279.
129. Kleinerman R.A., Tucker M.A., Abramson D.H., et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. JNatl Cancer Inst 2007, 99:24-31.
130. Shinohara E.T., DeWees T., Perkins S.M. Subsequent malignancies and their effect on survival in patients with retinoblastoma. Pediatr Blood Cancer 2014, 61:116-119.
131. Kleinerman R.A., Tarone R.E., Abramson D.H., et al. Hereditary retinoblastoma and risk of lung cancer. JNatl Cancer Inst 2000, 92:2037-2039.
132. Yu C.L., Tucker M.A., Abramson D.H., et al. Cause-specific mortality in long-term survivors of retinoblastoma. JNatl Cancer Inst 2009, 101:581-591.
133. Kleinerman R.A., Yu C.L., Little M.P., et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. JClin Oncol 2012, 30:950-957.
134. Fletcher O., Easton D., Anderson K., et al. Lifetime risks of common cancers among retinoblastoma survivors. JNatl Cancer Inst 2004, 96:357-363.